

Breast Cancer[®]

U P D A T E

An Audio Review Journal for Nurses

Management of Breast Cancer in the Adjuvant and Metastatic Settings

EDITOR

Neil Love, MD

INTERVIEWS

Robert W Carlson, MD

Clifford Hudis, MD

Anne P O'Connor, RN, MSN, AOCN

*Additional comments by two
healthcare professionals with
breast cancer*



A Continuing Nursing Education Audio Series

STATEMENT OF NEED/TARGET AUDIENCE

Medical oncology, particularly breast cancer, is one of the most rapidly advancing and developing fields of medicine. The constant emergence of new systemic agents, new indications for existing systemic agents, novel therapies, clinical trials and research findings demands that oncology nurses remain dedicated to continuing education in order to offer their patients the best care possible. This program provides registered nurses access to the most up-to-date research developments in breast cancer and the opinions of oncology nurses and clinical investigators with experience and expertise in the field. This information can be effectively translated into everyday patient management decisions.

PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *BREAST CANCER UPDATE FOR NURSES*

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings.
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings.
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings.
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse.
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings.
- Discuss psychosocial and emotional needs of caregivers, patients and their loved ones associated with the diagnosis and treatment of breast cancer.

ACCREDITATION STATEMENTS

This educational activity for 2.7 contact hours is provided by Research To Practice during the period of August 2007 through August 2008.

Research To Practice is an approved provider of continuing nursing education by the New Jersey State Nurses Association, Provider Number P215-01/07-10. NJSNA is accredited by the ANCC Commission on Accreditation. Provider Approval is valid through January 31, 2010.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Evaluation Form. The corresponding website BreastCancerUpdate.com/Nurses also includes links to relevant abstracts and full-text articles.

The Post-test and Evaluation Form may be completed in this book and either mailed to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131 or faxed to (800) 447-4310. They may also be completed online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

This program is supported by education grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.

If you would like to discontinue your complimentary subscription to *Breast Cancer Update for Nurses*, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

Breast Cancer®

U P D A T E

EDITOR

**Neil Love, MD**

Medical Oncologist
Editor, *Breast Cancer Update for Nurses*
Research To Practice
Miami, Florida

FACULTY AFFILIATIONS

**Robert W Carlson, MD**

Professor of Medicine
Division of Oncology and
Stanford Medical Informatics
Stanford University Medical Center
Stanford, California

**Clifford Hudis, MD**

Chief, Breast Cancer Medicine Service
Solid Tumor Division
Memorial Sloan-Kettering Cancer Center
New York, New York

**Anne P O'Connor, RN, MSN, AOCN**

Clinical Nurse Coordinator — Oncology
Lombardi Comprehensive Cancer Center
Washington, DC

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process: John Brebner, Richard Kaderman, PhD, Neil Love, MD, Paula Mateo, RN, BA, Donna Neil, RNC, Douglas Paley, Margaret Peng, Fredrica Preston, RNC, NP, AOCN, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Carlson — Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Taiho Pharmaceutical Co Ltd; Consulting Fees: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Pfizer Inc. **Dr Hudis** — Consulting Fees: AstraZeneca Pharmaceuticals LP, Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Kosan Biosciences, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Contracted Research: Breast Cancer Research Foundation, Kosan Biosciences, National Cancer Institute, National Institutes of Health; Shareholder: Genomic Health Inc.

Ms O'Connor — Shareholder: Abraxis BioScience.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Breast Cancer Update for Nurses — Issue 4, 2007**QUESTIONS (PLEASE CIRCLE ANSWER):**

1. Which schedule of administration for an LHRH agonist is more effective in achieving continued ovarian suppression in a premenopausal woman?
 - a. Monthly
 - b. Every three months
2. In the EFECT study, comparing fulvestrant to exemestane for postmenopausal women with advanced breast cancer, which therapy demonstrated a significantly greater rate of response and time to disease progression?
 - a. Fulvestrant
 - b. Exemestane
 - c. Fulvestrant and exemestane were about the same
3. Which of the following endocrine agents is a selective estrogen receptor modulator, with both estrogen-promoting and estrogen-antagonizing effects?
 - a. Tamoxifen
 - b. Anastrozole
 - c. Fulvestrant
 - d. Exemestane
4. In an ECOG trial comparing paclitaxel with or without bevacizumab in the metastatic setting, the addition of bevacizumab significantly _____ the duration of progression-free survival.
 - a. Increased
 - b. Decreased
5. Which of the following side effects is commonly associated with capecitabine?
 - a. Alopecia areata
 - b. Hand-foot syndrome
 - c. Bone loss
 - d. Uterine cancer
6. Premedicating patients with antihistamines and/or dexamethasone to avoid hypersensitivity reactions _____ required when administering *nab* paclitaxel.
 - a. Is
 - b. Is not
7. Adjuvant clinical trials comparing aromatase inhibitors to tamoxifen for postmenopausal women with hormone receptor-positive breast cancer have demonstrated which of the following?
 - a. Aromatase inhibitors result in bone loss
 - b. Aromatase inhibitors are not associated with uterine cancer
 - c. Aromatase inhibitors are more effective in reducing the risk of recurrence
 - d. All of the above
8. In a clinical trial that compared doxorubicin/cyclophosphamide to docetaxel/cyclophosphamide in the adjuvant setting, which regimen was more effective in lowering the risk of recurrence?
 - a. Doxorubicin/cyclophosphamide
 - b. Docetaxel/cyclophosphamide
9. Based on the *Oncotype DX™* assay, patients with a high recurrence score have a _____ chance of benefiting from adjuvant chemotherapy than patients with a low recurrence score.
 - a. Greater
 - b. Lesser
10. The TAnDEM trial, comparing anastrozole with or without trastuzumab for women with ER-positive, HER2-overexpressing metastatic breast cancer, demonstrated a significantly prolonged progression-free survival among patients who received _____
 - a. Anastrozole with trastuzumab
 - b. Anastrozole without trastuzumab

EVALUATION FORM

Breast Cancer Update for Nurses — Issue 4, 2007

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this Evaluation Form. A statement of credit will be issued only upon receipt of a completed Evaluation Form and a completed Post-test with a score of 70 percent or better.

Please answer the following questions by circling the appropriate rating:

5 =
Outstanding

4 =
Good

3 =
Satisfactory

2 =
Fair

1 =
Poor

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL

- To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer. 5 4 3 2 1

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings. 5 4 3 2 1
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings. 5 4 3 2 1
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings. 5 4 3 2 1
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse. 5 4 3 2 1
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings. 5 4 3 2 1
- Discuss psychosocial and emotional needs of caregivers, patients and their loved ones associated with the diagnosis and treatment of breast cancer. 5 4 3 2 1

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
Robert W Carlson, MD	5 4 3 2 1	5 4 3 2 1
Clifford Hudis, MD	5 4 3 2 1	5 4 3 2 1
Anne P O'Connor, RN, MSN, AOCN	5 4 3 2 1	5 4 3 2 1

OVERALL EFFECTIVENESS OF THE ACTIVITY

- Will assist me in improving patient care. 5 4 3 2 1
- Fulfilled my educational needs. 5 4 3 2 1
- Avoided commercial bias or influence. 5 4 3 2 1

IMPACT OF THE ACTIVITY

The information presented (check all that apply):

- Reinforced my current practice/treatment habits.
- Enhanced my current knowledge base.

EVALUATION FORM

Breast Cancer Update for Nurses — Issue 4, 2007

IMPACT OF THE ACTIVITY (CONTINUED)

Will the information presented cause you to make any changes in your practice?

- Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

.....
.....

If yes, how committed are you to making these changes?

(5 = very committed; 1 = not at all committed)..... 5 4 3 2 1

FUTURE ACTIVITIES

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes No

Please list any other topics that would be of interest to you for future educational activities:

.....
.....

Additional comments about this activity:

.....
.....

FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

REQUEST FOR CREDIT — please print clearly

Name:..... Degree:.....

Organization:..... Specialty:.....

Address:

City, State, Zip:.....

Telephone:..... Fax:..... Email:.....

Signature:..... Date:.....

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

To obtain credit, complete the Post-test and Evaluation Form and mail to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131, fax to (800) 447-4310 or complete both online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

Breast Cancer®

U P D A T E

Editor/CME Director	Neil Love, MD
Managing Editor	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Senior Director, Medical Affairs	Aviva Asnis-Alibozek, PA-C, MPAS
Writers	Lilliam Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng John Brebner Ginelle Suarez Erin Wall
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Graphic Designers	Jason Cunnius Tamara Dabney Shantia Daniel Elisa Stambouli
Senior Production Editor	Alexis Oneca
Traffic Manager	Tere Sosa
Copy Editors	Dave Amber Margo Harris Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager	Rena Chiarelli
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.com
For CNE Information	Email: CNE@ResearchToPractice.com

Copyright © 2007 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Breast Cancer®

U P D A T E

Copyright © 2007 Research To Practice.

This program is supported by education grants from Abraxis BioScience,
AstraZeneca Pharmaceuticals LP, Genentech BioOncology,
Genomic Health Inc and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: August 2007

Release date: August 2007

Expiration date: August 2008

Contact hours: 2.7